DZ3007A1 - Analogues de (1 R, CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentène-1-methanol comme agents antiviraux. - Google Patents

Analogues de (1 R, CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentène-1-methanol comme agents antiviraux.

Info

Publication number
DZ3007A1
DZ3007A1 DZ000019A DZ000019A DZ3007A1 DZ 3007 A1 DZ3007 A1 DZ 3007A1 DZ 000019 A DZ000019 A DZ 000019A DZ 000019 A DZ000019 A DZ 000019A DZ 3007 A1 DZ3007 A1 DZ 3007A1
Authority
DZ
Algeria
Prior art keywords
purin
cyclopentene
analogs
cis
methanol
Prior art date
Application number
DZ000019A
Other languages
English (en)
French (fr)
Inventor
Susan Mary Daluge
Christopher Mcguigan
Original Assignee
Glaxo Group Ltd
Gbuniversity College Cardiff C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903090.0A external-priority patent/GB9903090D0/en
Application filed by Glaxo Group Ltd, Gbuniversity College Cardiff C filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DZ3007A1 publication Critical patent/DZ3007A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DZ000019A 1999-02-12 2000-03-09 Analogues de (1 R, CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentène-1-methanol comme agents antiviraux. DZ3007A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903090.0A GB9903090D0 (en) 1999-02-12 1999-02-12 Therapeutic compounds
US17020599P 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
DZ3007A1 true DZ3007A1 (fr) 2003-03-27

Family

ID=26315118

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ000019A DZ3007A1 (fr) 1999-02-12 2000-03-09 Analogues de (1 R, CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentène-1-methanol comme agents antiviraux.

Country Status (24)

Country Link
US (1) US7115590B1 (https=)
EP (1) EP1150988B1 (https=)
JP (1) JP2002536452A (https=)
KR (1) KR20010102082A (https=)
CN (1) CN1346360A (https=)
AR (1) AR031975A1 (https=)
AT (1) ATE241633T1 (https=)
AU (1) AU772478B2 (https=)
BR (1) BR0008135A (https=)
CA (1) CA2362662A1 (https=)
CZ (1) CZ20012908A3 (https=)
DE (1) DE60002986T2 (https=)
DK (1) DK1150988T3 (https=)
DZ (1) DZ3007A1 (https=)
ES (1) ES2200820T3 (https=)
HK (1) HK1039337B (https=)
HU (1) HUP0105476A3 (https=)
IL (1) IL144647A0 (https=)
NO (1) NO20013910L (https=)
NZ (1) NZ513450A (https=)
PL (1) PL204458B1 (https=)
PT (1) PT1150988E (https=)
TR (1) TR200102313T2 (https=)
WO (1) WO2000047591A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042255A1 (en) * 1999-12-10 2001-06-14 Glaxo Group Limited (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのd−アミノ酸化合物
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
WO2001042255A1 (en) * 1999-12-10 2001-06-14 Glaxo Group Limited (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Also Published As

Publication number Publication date
PL350023A1 (en) 2002-10-21
CN1346360A (zh) 2002-04-24
AU2671300A (en) 2000-08-29
DK1150988T3 (da) 2003-09-29
DE60002986T2 (de) 2004-05-19
AR031975A1 (es) 2003-10-22
ES2200820T3 (es) 2004-03-16
HUP0105476A2 (en) 2002-06-29
US7115590B1 (en) 2006-10-03
NO20013910L (no) 2001-10-10
ATE241633T1 (de) 2003-06-15
EP1150988B1 (en) 2003-05-28
CZ20012908A3 (cs) 2002-10-16
HK1039337A1 (en) 2002-04-19
HK1039337B (en) 2003-11-21
JP2002536452A (ja) 2002-10-29
IL144647A0 (en) 2002-05-23
TR200102313T2 (tr) 2002-03-21
CA2362662A1 (en) 2000-08-17
KR20010102082A (ko) 2001-11-15
AU772478B2 (en) 2004-04-29
NZ513450A (en) 2004-03-26
PT1150988E (pt) 2003-10-31
NO20013910D0 (no) 2001-08-10
PL204458B1 (pl) 2010-01-29
WO2000047591A1 (en) 2000-08-17
DE60002986D1 (en) 2003-07-03
HUP0105476A3 (en) 2002-08-28
EP1150988A1 (en) 2001-11-07
BR0008135A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
DZ3007A1 (fr) Analogues de (1 R, CIS)-4-(6-amino-9H-purin-9-YL)-2-cyclopentène-1-methanol comme agents antiviraux.
EP1353683A4 (en) ANALOGS BY GHRELIN
PT1225874E (pt) Composicoes antivirais.
FR12C0041I2 (fr) Analogues de somatostatine
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
DE69920035D1 (de) Hochkonzentrierte wässrige glyphosatzusammensetzungen
AP2002002529A0 (en) 2,4-Diaminopyrimidine compounds useful as immunosupressants
IL144171A0 (en) Quinolinecarboxamides as antiviral agents
AP2003002932A0 (en) Thiophene derivatives as antiviral agents for flavviirus infection.
HUP0202812A3 (en) Novel bicyclonucleoside analogues
IL132188A0 (en) 4,4- Disubstituted-3,4-dihydro-2 (H)-quinazolineones useful as hiv reverse transcriptase inhibitors
GB0128526D0 (en) Nucleotide analogues
MXPA03007595A (es) Analogos de acido ascorbico para metalorradiofarmaceuticos.
DE69824822D1 (de) Wässerige Antischaumzusammensetzungen
ZA976242B (en) Illudin analogs useful as antitumor agents.
MXPA03000107A (es) Pirroloquinolonas como agentes antivirales.
EG23909A (en) Vatamin d, analogs
AU7810098A (en) 9-oxa prostaglandin analogs as ocular hypotensives
ATE377068T1 (de) Tensidzusammensetzungen, verbesserungsmittel enthaltend
DK1140937T3 (da) Antivirale nucleosid-analoger
EP1568704A4 (en) NOVEL 2 ', 5'-OLIGOADENIC ACID ANALOG
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
EP1211241A4 (en) ANALOG OF PROSTAGLANDIN E
AU2068901A (en) Analogs of (1s, cis)-4-(2-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral
GC0000195A (en) Benzoamido- and thiophenecarboxyamido-1,2,3,4-tetrahydroisoquinol-7-ine compunds as anticonvulsant agents